Fundraising FoxCriteria Bio Ventures — 2026 Investments
1 investments dated 2026 · listed companies and verified rows first · show all
Tolerance Biotolerancebio.cominJun 2026
Tolerance Bio develops therapeutics targeting the thymus—the regulator of immune tolerance—to preserve, restore, and manipulate its function and extend health span.
BiotechDeep TechLongevityPhiladelphia, US
Francisco Leon(Executive Officer, Director)inPhilip Ball(Executive Officer, Director)Justin Vogel(Executive Officer, Director)in
BoardDamia Tormo Carulla(Director)Pablo Cironi(Director)inRobert Goldstein(Director)
Co-investorsBioAdvanceBen Franklin Technology PartnersColumbus Venture Partners
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.